Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.4% – Here’s What Happened

Shares of Johnson & Johnson (NYSE:JNJ) traded down 1.4% during mid-day trading on Thursday . The company traded as low as $263.83 and last traded at $266.0960. 7,125,367 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 8,207,116 shares. The stock had previously closed at $270.00.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: China approved JNJ’s oral psoriasis treatment, expanding the drug’s commercial opportunity in a major pharmaceutical market. However, competition from AbbVie and Bristol Myers Squibb could limit its eventual market share. China approves J&J’s oral psoriasis pill
• Positive Sentiment: The FDA approved JNJ’s Imaavy for patients aged 12 and older with warm autoimmune hemolytic anemia, giving the company a second FDA win in two months and opening a new rare-disease market. Johnson & Johnson Just Got a Big FDA Win
• Positive Sentiment: Analysts and investment commentary highlight JNJ’s defensive dividend profile, broad healthcare portfolio and growth outside STELARA. One report said the remainder of Innovative Medicine is growing at more than 14%, potentially offsetting some patent-cliff concerns. How Much Upside Is Left in JNJ Stock?
• Neutral Sentiment: Imaavy’s approval is strategically useful, but the initial indication addresses a rare disease and is unlikely by itself to materially change JNJ’s valuation. Investors will focus on adoption, additional indications and revenue scale. J&J’s First Anemia Approval Meets a $652 Billion Reality
• Negative Sentiment: Investors remain focused on the STELARA patent cliff and the competitive environment in immunology and psoriasis, risks that may weigh on sentiment even as newer medicines and approvals provide growth opportunities.
• Negative Sentiment: Recent commentary notes that JNJ’s shares declined more than the broader market, suggesting some investors may be taking profits or reassessing the stock’s valuation after its strong run. JNJ Sees a More Significant Dip Than Broader Market

Analyst Ratings Changes

Several brokerages recently weighed in on JNJ. Bank of America lifted their price objective on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research report on Friday, July 10th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a report on Monday, August 3rd. Scotiabank restated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Citigroup increased their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $268.22.

Johnson & Johnson Price Performance

The stock has a 50 day moving average of $257.32 and a two-hundred day moving average of $243.59. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market cap of $641.26 billion, a PE ratio of 30.83, a PEG ratio of 2.61 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same period last year, the company posted $2.77 earnings per share. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 63,972 shares of company stock worth $16,245,605. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Tucker Asset Management LLC lifted its position in Johnson & Johnson by 173.4% in the 2nd quarter. Tucker Asset Management LLC now owns 5,011 shares of the company’s stock worth $1,273,000 after buying an additional 3,178 shares in the last quarter. Principia Wealth Advisory LLC increased its stake in shares of Johnson & Johnson by 208.7% in the second quarter. Principia Wealth Advisory LLC now owns 815 shares of the company’s stock worth $207,000 after acquiring an additional 551 shares during the last quarter. Brown Financial Advisors raised its holdings in shares of Johnson & Johnson by 10.6% during the second quarter. Brown Financial Advisors now owns 7,216 shares of the company’s stock worth $1,833,000 after acquiring an additional 694 shares in the last quarter. Advus Financial Partners LLC boosted its position in Johnson & Johnson by 4.5% during the second quarter. Advus Financial Partners LLC now owns 7,402 shares of the company’s stock valued at $1,880,000 after purchasing an additional 317 shares during the last quarter. Finally, Groupe la Francaise boosted its position in Johnson & Johnson by 991.4% during the second quarter. Groupe la Francaise now owns 198,681 shares of the company’s stock valued at $50,466,000 after purchasing an additional 180,477 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.